Th1-adapted regulatory T cells in tumor immunity and inflammatory diseases
International Immunology · 14.07.2026
DOI: 10.1093/intimm/dxag038 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, online erschienen am 14.07.2026. Verfasst von Ayumi Kuratani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency, Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Regulatory T cells (Tregs) play an essential role in maintaining immune tolerance and controlling excessive inflammation. Although traditionally viewed as a stable lineage dedicated to broad immunosuppression, accumulating evidence has revealed that Tregs exhibit remarkable heterogeneity and functional adaptability, allowing them to undergo specialization in response to local inflammatory environments. Among these specialized subsets, Th1-type Tregs (Th1-Tregs), characterized by the co-expression of Foxp3 and the transcription factor T-bet, have emerged as key regulators of type 1 immune responses. By expressing the chemokine receptor CXCR3, these cells localize to IFN-γ–rich inflammatory sites and selectively modulate Th1-driven immune circuits. Recent studies have demonstrated that Th1-Tregs play context-dependent roles across diverse pathological conditions. In the tumor microenvironment, they suppress cytotoxic immunity and contribute to tumor immune evasion. In contrast, during autoimmune diseases and acute infections, Th1-adapted regulatory programs protect host tissues by restraining excessive inflammation. These findings highlight how Tregs dynamically adapt to local inflammatory environments to control type 1 immune responses in different tissues. In this review, we summarize the molecular mechanisms underlying Th1-Treg differentiation and discuss how these specialized regulatory programs shape immune responses across different disease contexts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
- Laboratory of Immunoparasitology, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
- Department of Infectious Disease Control, Faculty of Medicine, Oita University, Oita 879-5593, Japan.
- Division of Pathophysiology, Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Oita 879-5593, Japan.
- Department of Immunoparasitology, Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka 565-0871, Japan.
Förderung
- Japan Science and Technology Agency
- Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Joint Usage and Joint Research Programs of the Institute of Advanced Medical Sciences
- Tokushima University
- Takeda Science Foundation
- Mochida Memorial Foundation
- Astellas Foundation for Research on Metabolic Disorders
Zitieren
APA
Kuratani, A., Okamoto, M., Kobayashi, T., & Yamamoto, M. (2026). Th1-adapted regulatory T cells in tumor immunity and inflammatory diseases. International Immunology. https://doi.org/10.1093/intimm/dxag038
Vancouver
Kuratani A, Okamoto M, Kobayashi T, Yamamoto M. Th1-adapted regulatory T cells in tumor immunity and inflammatory diseases. International Immunology. 2026. doi:10.1093/intimm/dxag038
BibTeX
@article{Kuratani2026,
author = {Kuratani, Ayumi and Okamoto, Masaaki and Kobayashi, Takashi and Yamamoto, Masahiro},
title = {Th1-adapted regulatory T cells in tumor immunity and inflammatory diseases},
journal = {International Immunology},
year = {2026},
doi = {10.1093/intimm/dxag038}
}
EUVIMED